Assessing Medline (MDLN) Valuation After Recent Share Price Momentum

Simply Wall St.

Apr 14

Medline (MDLN) is back in focus after a recent move in its share price, with short term gains over the past week and month prompting fresh questions about how investors are valuing the business. See ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2627441671"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627441671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627441671?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-04-14 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627441671","market":"us","top_or_hot":-1,"title":"Assessing Medline (MDLN) Valuation After Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>Medline (MDLN) is back in focus after a recent move in its share price, with short term gains over the past week and month prompting fresh questions about how investors are valuing the business. See ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/assessing-medline-mdln-valuation-after-recent-share-price-mo-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Medline (MDLN) Valuation After Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Medline (MDLN) Valuation After Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 20:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/assessing-medline-mdln-valuation-after-recent-share-price-mo-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medline (MDLN) is back in focus after a recent move in its share price, with short term gains over the past week and month prompting fresh questions about how investors are valuing the business. See ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/assessing-medline-mdln-valuation-after-recent-share-price-mo-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/assessing-medline-mdln-valuation-after-recent-share-price-mo-2","article_id":"2627441671","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/assessing-medline-mdln-valuation-after-recent-share-price-mo-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627441671","pubTimestamp":1776168583,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Medline (MDLN) is back in focus after a recent move in its share price, with short term gains over the past week and month prompting fresh questions about how investors are valuing the business.\nSee our latest analysis for Medline.\nThe recent momentum is not limited to a single session, with a 1 day share price return of 3.55% sitting within a broader pattern that includes a 16.25% year to date share price return. This suggests interest has been building rather than fading.\nIf you are looking...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","MDLN":"Medline Inc","BK4198":"医疗保健用品"},"translate_title":"在近期股价势头后评估Medline(MDLN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDLN":1.5,"DCF":1},"content_text":"Medline (MDLN) is back in focus after a recent move in its share price, with short term gains over the past week and month prompting fresh questions about how investors are valuing the business. See our latest analysis for Medline. The recent momentum is not limited to a single session, with a 1 day share price return of 3.55% sitting within a broader pattern that includes a 16.25% year to date share price return. This suggests interest has been building rather than fading. If you are looking beyond Medline for ideas in healthcare and adjacent themes, this is a good time to broaden your watchlist with 34 healthcare AI stocks With Medline trading at $47.22 and sitting around a 7% intrinsic discount and a 13% discount to analyst targets, the key question is whether there is still a buying opportunity here or if the market is already accounting for future growth. AdvertisementPrice to earnings of 33.1x: Is it justified? Medline screens as expensive on a P/E basis, with its 33.1x ratio sitting above both its direct peer group and the broader US Medical Equipment industry. The P/E multiple compares the current share price to earnings per share, so a higher figure usually means the market is paying more today for each dollar of current earnings. For a healthcare supplier of Medline's scale, this often reflects expectations that earnings will improve over time rather than any single quarter's result. Here, forecasts point to earnings growth of about 16.6% per year, ahead of the wider US market expectation of 15.7%, while revenue is projected to grow at 7.2% per year. At the same time, current return on equity is 6% and is expected to remain in the low double digits. This suggests the market is placing a relatively rich price on these future profit streams. Compared to the US Medical Equipment industry average P/E of 26.2x and a peer group average of 24.2x, Medline's 33.1x multiple stands out as meaningfully higher. That gap indicates investors are paying a sizeable premium relative to both the sector and its closest comparisons. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-earnings of 33.1x. However, that premium P/E also leaves little room for disappointment if supply chain services slow or if margins in core med surg products come under pressure. Find out about the key risks to this Medline narrative. Another view: DCF suggests a different story While the 33.1x P/E points to a premium price, our DCF model paints a softer picture. On that view, Medline trades at $47.22 versus an estimated future cash flow value of $50.81, roughly a 7.1% gap. So is the P/E multiple too harsh, or is the cash flow view too generous? Look into how the SWS DCF model arrives at its fair value. MDLN Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Medline for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of risks and rewards feels finely balanced, it is worth looking over the numbers yourself and deciding where you stand. To see how the key risks and potential rewards stack up side by side, take a closer look at 3 key rewards and 1 important warning sign Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at a single stock. Use the tools available to compare opportunities and spot potential mismatches before everyone else does.  Target potential mispricings by scanning for companies that combine quality fundamentals with room for a re rating through the 55 high quality undervalued stocks. Strengthen your downside protection by focusing on businesses with robust finances using the solid balance sheet and fundamentals stocks screener (41 results). Spot early opportunities that the market may be overlooking by filtering for a curated set of under the radar names with the screener containing 23 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}